Life Sciences Collaboration Deals a Mainstay of Biotech Industry – Here Are the Tax Consequences

October.21.2022

In this Law360 article, partners Peter Connors and David Schulman, along with Michael Hirschfeld, a managing director at Andersen Tax LLC, provide guidance on the key tax considerations in play with Life Sciences Collaboration Deals.

The article is an in-depth analysis of what the authors describe as a mainstay of the biotech industry.

Read the full article here.

Authors

Peter Connors Partner, Steuern, Unternehmensbesteuerung

New York

See my bio

D:+1 212 506 5120
E: [email protected]

Practice:

Finance Sector
Steuern
Unternehmensbesteuerung
Internationales Steuerrecht
Renewable Energy
Restructuring
Swaps und andere Hedges
Steuerstreitigkeiten
Blockchain and Virtual Currency

vCard

See full bio

Peter Connors Partner

New York

According to Chambers, his peers state that Peter is “an outstanding international tax practitioner” who is admired for the strength of his activity in the field of cross-border transactions and is ”an excellent lawyer who has a diverse practice.” According to Legal 500, “Peter Connors is well-versed in terms of the taxation of financial products and financial institutions.”

Peter serves as President of the USA Branch of the International Fiscal Association. From 2020 to 2021, he was President of the American College of Tax Counsel. He now serves as chair of the College’s Amicus Brief Committee and on the ABA Tax Section’s Distinguished Service Award Committee.

Before joining Orrick, Peter was a principal in the International Tax Services Group of Ernst & Young in New York.

A prolific author, with over 150 published articles on tax-related subjects, Peter is considered a thought leader in the field of taxation. He is co-author of T.M. Portfolio 543 -2d (”The Mark to Market Rules of Section 475") and the author of T.M. Portfolio 909-3d (”The Branch-Related Taxes of Section 884 “).

He has been recognized by every edition of Best Lawyers in America since 2015.

David Schulman Partner, Capital Markets, Mergers & Acquisitions

Washington, D.C.

See my bio

D:+1 202 339 8654
E: [email protected]

Practice:

Life Sciences Sector
Technology & Innovation Sector
Capital Markets
Mergers & Acquisitions
Technology Companies Group
Technology Transactions

vCard

See full bio

David Schulman Partner

Washington, D.C.

He provides strategic guidance on transactions involving mergers, acquisitions, collaborations, strategic alliances, licenses, capital markets, royalty and revenue-sharing and other financings for pharmaceutical and biotechnology companies and financial sponsors.

David is highly ranked for his life sciences work by Chambers USA and Chambers Global, with clients recognizing him as “one of the best business and corporate lawyers in the life sciences sector” with “a deep knowledge of the industry, which he successfully combines with great legal skills.” He has also been recognized by The Legal 500 and is listed as a “Life Sciences Star” in LMG Life Sciences.

Prior to joining Orrick, David was a partner with Dechert LLP, based in its Washington, D.C., and London offices and was a co-head of their Life Sciences practice. He is currently a member of the Board of Overseers of the School of Arts and Sciences of the University of Pennsylvania.